Phase II trial of Allovectin-7®, for metastatic melanoma

Journal of Drugs in Dermatology, Sept-Oct, 2004

This study is currently recruiting patients.

Sponsored by Vical

The purpose of this clinical trial is to determine if Allovectin-7[R], an experimental gene-based immunotherapy, can shrink melanoma tumors. The trial will also examine if this treatment can improve the time to disease progression.

Condition            Treatment or Intervention       Phase

Melanoma             Gene Transfer: Allovectin-7[R]  Phase II
Metastatic Melanoma
Malignant Melanoma
Skin Cancer

Study ID Numbers: VCL-1005-208

NLM Identifier: NCT00044356